Hodgkin Disease
104
4
12
63
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
34 trials with published results (33%)
Research Maturity
63 completed trials (61% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
20.2%
21 terminated out of 104 trials
75.0%
-11.6% vs benchmark
6%
6 trials in Phase 3/4
54%
34 of 63 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 63 completed trials
Clinical Trials (104)
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Tissue Collection for Studies of Lymph Cancer
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR)
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospective Study on ≥200 Adult Female HL Patients Treated With ≥1 MBVD Cycle (NPLD, Bleomycin, Vinblastine, Dacarbazine). It Investigates Breast Cancer Incidence Post-treatment.